Psoriasis affects 3% of the population worldwide, and there is no known cure. Psoriasis is associated with an
increased risk of psoriatic arthritis, lymphomas, cardiovascular disease, and Crohn’s disease. Psoriasis treatments
today include steroid and vitamin D3 cream, ultraviolet light, and immune systemsuppressing medications such as
methotrexate.
The T cells responsible for psoriasis are Th1 and Th l7 cells. IL-22, produced by Th17 cells, is crucial for the
proliferation of keratinocytes. IL-22 with the help of IL-17 can induce the critical events of psoriasis. To maintain
Th17 cells, IL-23 is required, and it is released from tumor necrosis factor-alpha (TNF-alpha) induced pathways. The
pathophysiology of psoriasis involves RORC (retinoic acid receptor-related orphan nuclear receptor gamma) as a
critical transcription factor for the development of Th17 cells. FDA has approved an antibody Secukinumab® targeting
TNF-α for the treatment of psoriasis. Other FDA approved drugs are Tremfya® targeting IL23 for treatment of moderate
to severe plaque psoriasis and Taltz® that blocks IL17 for treatment of plaque psoriasis.
Metadichol® a nanoformulation of long-chain lipid alcohols derived from food is a TNF-alpha inhibitor and also
binds to Vitamin D receptor (VDR) that could have beneficial effects on Psoriasis. VDR modulates Th1-mediated
inflammatory disease like psoriasis. We now present evidence that Metadichol is an inverse agonist of RORγt and
AHR (Aryl Hydrocarbon Receptor) thus controlling Th17, IL17 and IL22. Being a TNF-alpha inhibitor, it can control IL23
thus blocking the significant pathways that exacerbate psoriasis. We present case studies of 7 patients afflicted with
psoriasis and skin related conditions and how treatment with Metadichol resolved the underlying disease. Metadichol®
has properties that allow its use as a safe nontoxic solution to combating the growing number of psoriasis cases